Press Releases

Nov 28, 2022

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

Nov 13, 2022

Immutep Receives Australian R&D Tax Incentive

Nov 09, 2022

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Nov 09, 2022

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

Nov 09, 2022

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination